GC Green Cross Achieves Record Results Driven by Aliglo... Turns Fourth Quarter Profit for First Time in 7 Years
Annual Revenue Reaches 1.9913 Trillion Won, Operating Profit Hits 69.1 Billion Won
GC Green Cross has marked a turning point in its business structure by posting a profit in the fourth quarter?a period long seen as a symbol of chronic underperformance?for the first time in seven years. The rapid expansion of high-margin blood product sales in the United States also propelled the company to its highest annual performance since its founding.
On January 26, GC Green Cross announced via public disclosure that, on a consolidated financial statement basis, its 2025 revenue reached 1.9913 trillion won, an 18.5% increase compared to the previous year. Operating profit for the same period more than doubled to 69.1 billion won. Both revenue and profitability showed a distinct trend of improvement.
The turnaround in the fourth quarter was particularly notable. Last year’s fourth-quarter revenue was 497.8 billion won, with operating profit at 4.6 billion won. This marks a departure from the previous structure in which the company had recorded operating losses in the fourth quarter every year since 2018, due to a combination of declining flu vaccine sales and ongoing R&D expenditures.
The main driver of the improved performance was ‘Aliglo,’ an intravenous immunoglobulin product. Aliglo has rapidly expanded its market share in the United States since receiving FDA approval for commercial sale in 2024. Last year, U.S. sales exceeded 106 million dollars (approximately 153.1 billion won).
The company’s existing flagship products also continued to grow. ‘Hunterase,’ a treatment for Hunter syndrome, achieved record sales of 74.4 billion won last year, up about 20% from the previous year. The chickenpox vaccine ‘Varicella’ also saw its sales double year-on-year to 32.1 billion won.
On a separate financial statement basis, plasma fractionation products accounted for the largest portion at 560.2 billion won. This was followed by vaccine products at 300.6 billion won, prescription drugs at 479.8 billion won, and over-the-counter and consumer healthcare products at 119.7 billion won. The overseas plasma business also showed gradual improvement; U.S.-based ABO Plasma, acquired early last year, significantly reduced its losses in the fourth quarter.
Subsidiaries included in the consolidated statements also saw overall stabilization in their results. GC Cell recorded revenue of 165.5 billion won, reducing its deficit by 31%. GC Green Cross Wellbeing maintained a profit structure focused on its core business, with revenue of 164.7 billion won and operating profit of 17.3 billion won. The company explained that GC Cell’s net income reflects a one-off accounting adjustment related to the fair value assessment of goodwill from a past merger, which did not involve any cash outflow.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
A GC Green Cross representative stated, “With the solid performance of our existing businesses and improved profitability at our subsidiaries, we expect to achieve continued growth this year as well.”
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.